- Pharmaceutical companies
- Africa
- South Africa
- Gilead Sciences
Gilead Sciences in South Africa
E-mail: ACMedInfo@gilead.com, drugsafetysouthafrica@gilead.com
Address:
-
Gilead Sciences South Africa
Ground Floor, Mac Mac Building Maxwell Office Park Magwa Crescent Waterfall Johannesburg 2090 South Africa
Phone: +27103461920
Other Gilead Sciences's locations around the world
Europe
North America
Africa
Oceania
Clinical Trials sponsored by Gilead Sciences
-
Gilead SciencesIkke rekrutterer endnu
-
Gilead SciencesRekruttering
-
Gilead SciencesRekrutteringColitis ulcerosaForenede Stater
-
Gilead SciencesRekrutteringFaste tumorerAustralien, Forenede Stater, Canada
-
Gilead SciencesRekrutteringKronisk hepatitis D-infektionForenede Stater
-
Gilead SciencesRekrutteringKronisk hepatitis D-infektionØstrig, Frankrig, Tyskland, Spanien, Rumænien
-
Gilead SciencesRekrutteringHIV-1-infektionForenede Stater, Thailand, Dominikanske republik
-
Gilead SciencesAktiv, ikke rekrutterendeMetastatisk tyktarmskræftForenede Stater, Spanien, Australien, Hong Kong, Frankrig, Belgien, Canada, Puerto Rico, Tyskland, Italien
-
Gilead SciencesAfsluttetAkut myeloid leukæmiForenede Stater, Spanien, Tyskland, Israel, Det Forenede Kongerige, Taiwan, Korea, Republikken, Australien, Belgien, Hong Kong, Frankrig, Holland, Italien, Canada, Østrig, Tjekkiet, Ungarn, Norge, Polen, Schweiz
-
Gilead SciencesAktiv, ikke rekrutterendeMetastatisk fast tumorForenede Stater, Spanien, Frankrig, Hong Kong, Australien, Belgien, Taiwan, Canada
About Gilead Sciences
At Gilead, we’re committed to creating possible. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.